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Abstract
Chronic kidney disease (CKD) is a major cause of morbidity and premature mortality and represents a significant global 
public health issue. Underlying this burden are the many complications of CKD, including mineral and bone disorders, ane-
mia, and accelerated cardiovascular disease. Hyperphosphatemia and elevated levels of fibroblast growth factor 23 (FGF23) 
have been identified as key independent risk factors for the adverse cardiovascular outcomes that frequently occur in patients 
with CKD.  Auryxia® (ferric citrate; Keryx Biopharmaceuticals, Inc., Boston, MA, USA) is an iron-based compound with 
distinctive chemical characteristics and a mechanism of action that render it dually effective as a therapy in patients with 
CKD; it has been approved as a phosphate binder for the control of serum phosphate levels in adult CKD patients treated 
with dialysis and as an iron replacement product for the treatment of iron deficiency anemia in adult CKD patients not treated 
with dialysis. This review focuses on Auryxia, its mechanism of action, and the clinical attributes that differentiate it from 
other, non-pharmaceutical-grade, commercially available forms of ferric citrate and from other commonly used phosphate 
binder and iron supplement therapies for patients with CKD. Consistent with the chemistry and mechanism of action of 
Auryxia, multiple clinical studies have demonstrated its efficacy in both lowering serum phosphate levels and improving iron 
parameters in patients with CKD. Levels of FGF23 decrease significantly with Auryxia treatment, but the effects associated 
with the cardiovascular system remain to be evaluated in longer-term studies.
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Key Points 
Patients with chronic kidney disease (CKD) frequently 
have high levels of phosphate and low levels of iron in 
the blood, both of which are associated with elevated 
risks of cardiovascular disease and death.
The drug Auryxia (ferric citrate) has a special formulation 
that enables it to both increase iron levels in patients with 
CKD who are not receiving dialysis and decrease phosphate 
levels in patients with CKD who are receiving dialysis.
1 Introduction
Chronic kidney disease (CKD) represents a major global 
public health concern [1]. The United States Renal Data 
System estimated that in 2017, 30 million American adults 
had CKD [2]. CKD is associated with serious comorbidi-
ties, most importantly cardiovascular disease [1, 2]. Further-
more, the financial burden of CKD is high; in the USA, with 
total Medicare expenditures exceeding $64 billion in 2015 
[2]. Magnifying this burden is the undertreatment of CKD 
[3], especially in the earlier stages of the disease, highlight-
ing the need for better awareness of all therapeutic options 
with regard to their efficacy, safety, tolerability, and cost 
effectiveness.
1.1  Perturbations of Bone and Mineral Metabolism 
and Iron Parameters in Chronic Kidney Disease
Alterations of bone and mineral metabolism and anemia are 
common and occur early in the course of CKD and when 
left untreated carry an increased risk for adverse outcomes 
[4, 5]. Approximately 36% of hemodialysis patients in the 
USA have hyperphosphatemia (when defined as a phosphate 
concentration > 5.5 mg/dL) [6], although older surveys cite 
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higher percentages [7–9]. Hyperphosphatemia is an inde-
pendent risk factor for cardiovascular events, and has been 
shown to be associated with a higher mortality rate [10, 11]; 
however, it is important to note that the evidence supporting 
the association between phosphorus levels and mortality is 
derived from observational studies, which are potentially 
subject to confounding. A National Health and Nutrition 
Examination Survey estimated that 15.4% of patients with 
CKD in the USA are anemic, defined as having blood hemo-
globin levels ≤ 12 g/dL in women and ≤ 13 g/dL in men, 
representing 4.8 million affected individuals [4]. As with 
hyperphosphatemia, patients with CKD who also have ane-
mia are at increased risk of cardiovascular disease and death, 
among other comorbidities [4]. It is expected that, in theory, 
successful treatment of hyperphosphatemia and anemia in 
patients with CKD could help avoid adverse clinical out-
comes; however, with the exception of renal replacement, 
no interventions have yet been proven to improve outcomes.
The pathophysiologic networks that regulate bone and 
mineral metabolism and iron distribution are complex. An 
increasing number of studies support the idea that fibro-
blast growth factor 23 (FGF23), a key phosphate-regulating 
hormone, is associated with adverse outcomes in CKD 
[12]. Along with parathyroid hormone (PTH), FGF23 is an 
important factor involved in the disordered bone and mineral 
metabolism that contributes to CKD morbidity and mortal-
ity [5, 12]. Normally, FGF23 regulates phosphate and vita-
min D metabolism through a negative endocrine feedback 
loop it shares with PTH; however, production of 1,25-dihy-
droxyvitamin  D3 is inhibited by FGF23 but stimulated by 
PTH, whereas both FGF23 and PTH share the phosphaturic 
effect [12–14]. In patients with early CKD, as renal func-
tion begins to decrease, compensatory increases in FGF23 
and PTH may help maintain normal phosphate balance, 
mainly by stimulating greater urinary phosphate excretion 
[13, 15]. These increases in FGF23 and PTH in early CKD 
precede frank hyperphosphatemia, which is observed only 
with advanced renal disease after the compensatory mecha-
nisms have been overwhelmed [13, 15]. In a cross-sectional 
study of patients representing a spectrum of CKD severity, 
increased FGF23 levels were significantly associated with 
deteriorating renal function [15]. For reasons that are not 
yet clear, FGF23 also may be related to the development of 
iron deficiency anemia; in a recent cohort study, elevated 
concentrations of FGF23 were associated with a higher inci-
dence of anemia, particularly in patients with iron deficiency 
[16]. Importantly, increased serum FGF23 concentrations 
are associated with increased risk of cardiovascular events 
and death in CKD [12]. Several studies have highlighted the 
relationships of inflammation and iron deficiency anemia, 
both commonly present in CKD, with FGF23 levels that rise 
early in the course of the disease [17–19]. Thus, interven-
tions that decrease levels of FGF23 may favorably affect 
several important outcomes in patients in CKD, although 
this has yet to be established in long-term clinical studies.
1.2  Treatment of Hyperphosphatemia and Iron 
Deficiency Anemia in Chronic Kidney Disease
With the high prevalence of hyperphosphatemia among 
hemodialysis patients in the USA, restoration of phosphate 
balance using phosphate binders has long been a therapeu-
tic goal in CKD management [7–9]. In the 1970s to 1990s, 
aluminum-based and then calcium-based phosphate bind-
ers were often used for the control of hyperphosphatemia 
in patients with end-stage renal disease [7, 20]. However, 
associations with aluminum toxicity for aluminum-based 
binders and hypercalcemia and metastatic calcification for 
calcium-based binders motivated the development of cal-
cium-free, aluminum-free phosphate binders [7, 20–22]. 
In fact, the Kidney Disease: Improving Global Outcomes 
(KDIGO) 2017 guidelines for CKD-mineral bone disorder 
recommend restricting the dose of calcium-based phosphate 
binders in adult patients with stage 3–5 CKD receiving 
phosphate-lowering treatment [23]. However, the Dialysis 
Clinical Outcomes Revisited trial, which compared mortal-
ity among hemodialysis patients treated with calcium-based 
phosphate binders and sevelamer hydrochloride, failed to 
demonstrate the superiority of the non-calcium-containing 
sevelamer hydrochloride with respect to death and hospi-
talization rates [24]. Ultimately, improvements in clinical 
outcomes in patients with hyperphosphatemia may not be 
achieved by improving phosphate balance alone.
Iron deficiency anemia in CKD has long been treated with 
iron supplementation using either oral or intravenous (IV) 
therapy [25]. The decision between oral and IV iron should 
involve an assessment of benefit and risk. Most oral iron 
formulations may be less expensive but are often associated 
with adverse gastrointestinal (GI) effects, whereas IV iron 
may be more effective than oral iron but carries the risks 
of adverse reactions during IV administration and potential 
for long-term iron overload [25–28]. IV administration may 
be the preferred route of administration of iron for hemodi-
alysis patients partly because it is easily administered dur-
ing hemodialysis; however, this is not necessarily true for 
patients that are not on dialysis (or are on peritoneal dialysis) 
[29].
1.3  Auryxia: an Iron‑Based Treatment 
for Hyperphosphatemia and Iron Deficiency 
Anemia in Chronic Kidney Disease
Iron-based compounds, such as ferric citrate  (Auryxia®; 
Keryx Biopharmaceuticals, Inc., Boston, MA, USA), repre-
sent a new category of phosphate binders [30]. Auryxia has 
the advantage of dual functionality (i.e. controlling serum 
959MOA of Auryxia
phosphate levels and treating iron deficiency anemia) [31]. 
In the USA, Auryxia is indicated as a phosphate binder 
for the control of serum phosphate levels in adult patients 
with CKD treated with dialysis and as an iron replacement 
product for the treatment of iron deficiency anemia in adult 
patients with CKD not on dialysis [31]. Similar ferric citrate 
products are approved for use in other countries under differ-
ent brand names. In the European Union, ferric citrate coor-
dination complex  (Fexeric® Keryx Biopharma UK Ltd, Lon-
don, UK) is indicated for the control of hyperphosphatemia 
in adult patients with CKD [32]. In Japan, ferric citrate 
hydrate  (Riona® Torii Pharmaceutical Co., Ltd., Tokyo, 
Japan) is indicated to treat hyperphosphatemia in patients 
with CKD [33, 34]. In Taiwan, ferric citrate  (Nephoxil®, 
Panion & BF Biotech Inc., Taipei, Taiwan) is indicated for 
controlling hyperphosphatemia in adult patients with CKD 
undergoing hemodialysis [35]. This review focuses on 
Auryxia, its mechanism of action, and the clinical attributes 
that differentiate it from other, non-pharmaceutical-grade, 
commercially available forms of ferric citrate and from other 
commonly used phosphate binder and iron supplement ther-
apies for patients with CKD.
2  Chemical Composition of the Active 
Pharmaceutical Ingredient (API) 
in Auryxia
The API of Auryxia is not a single compound but rather a 
solid mixture of ferric citrate coordination complexes (FCCCs) 
with the following chemical formula: iron (+ 3), x (anion of 
1,2,3-propanetricarboxylic acid, 2-hydroxy-), y  (H2O), where x 
ranges from 0.70 to 0.87 and y ranges from 1.9 to 3.3 [31, 36]. 
As opposed to iron salts, which readily dissociate into their 
component ions in water, the bonds that coordinate the central 
metal atom with the surrounding ligands allow the complex to 
retain its identity as a unit with properties different from those 
of its components. Furthermore, Auryxia has different proper-
ties from those of commercial-grade ferric citrate [36], which 
was the material investigated in early studies. Most important 
among these differences among ferric citrate preparations is 
that the API of Auryxia has a defined molar ratio of ferric iron 
 (Fe3+) to citrate anions [37], whereas ferric citrate from com-
mercial sources may have variable molar ratios of ferric iron, 
citric acid, and associated hydrates [36]. It is important to first 
establish what is known about ferric citrate in general before 
understanding more about the specific physicochemical profile 
of the pharmaceutical-grade ferric citrate that constitutes the 
API of Auryxia.
2.1  Structural Chemistry of Ferric Citrate
As already noted, “ferric citrate” is a common name for a large 
group of metallo-complexes comprising ferric ions  (Fe3+) and 
citrate ligands with various degrees of protonation. These com-
plexes are characterized by different iron nuclearities, ratios 
of iron to citrate, and ligand coordination modes. Naturally 
occurring ferric citrate complexes play an important role in 
iron solubilization, mobilization, and utilization in all forms 
of life [38]. Citric acid is an α-hydroxy tricarboxylic acid 
(Fig. 1), capable of binding ferric ions and forming a series of 
stable species in aqueous solution over a wide pH range [39]. 
This action prevents the hydrolysis of ferric ions that leads to 
the formation of insoluble ferric oxides and ferric hydroxides 
under physiological pH. It is known that iron levels in physi-
ological (i.e. biological, living) systems are regulated by citric 
acid chelation of ferric ions or through redox reactions of fer-
ric citrate [40, 41]. In medicine, it has long been known that 
citric acid enhances the bioavailability of iron [42], and several 
iron citrate preparations are commercially available for use 
as iron supplements in foods. Because ferric citrate can form 
a series of interrelated complexes, it is soluble over a broad 
range of pH in the stomach and intestine (where phosphate 
binding occurs) and in the duodenum (the primary site of oral 
iron absorption) [43].
Although ferric citrate complexes have been investigated 
and used clinically as iron supplements [44], no structural data 
were available until 1994. High solubility in aqueous solu-
tion and the many diverse species of ferric citrate complexes 
had been the main obstacles to obtaining single crystals for 
structural elucidation by x-ray crystallography. By introducing 
a variety of cations into solutions prepared by mixing ferric 
salts and sodium citrate or citric acid in water, several crys-
talline compounds were obtained and subjected to structural 
studies. To date, the crystal structures of five ferric citrate 
complexes are known in the literature (Fig. 2); these con-
sist of one mononuclear species,  [FeCitrate2]5− (complex 1) 
[45]; two dinuclear species,  [Fe2Citrate2(H2O)2]2− (complex 
2) and  [Fe2(HCitrate)3]3− (complex 3) [46]; one nonanuclear 
species,  [Fe9OCitrate8(H2O)3]7− (complex 4) [47]; and one 
trinuclear species,  [Fe3Citrate4H]6− (complex 5) [48]. Ferric 
citrate complex 2 appears to be particularly relevant to the 
physiologic interactions. The reports of Ferguson and cowork-
ers from the group of Johann Deisenhofer in 2002, as well as 
Sauter and Braun in 2004, showed that the dinuclear complex 
2 is recognized, absorbed, and transferred across membranes 
by the outer membrane transporter FecA in Escherichia coli, 
Fig. 1  Structure of citric acid
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establishing the biological relevance of this species [49, 50]. 
Earlier work had shown the remarkable kinetic stability of 
complex 2, as demonstrated by the recrystallization of its pyri-
dinium salt after the dissolution of the crude material in warm 
pure water; crystals usually grew slowly at room temperature 
over a period of approximately 3 to 6 days [46]. Such kinetic 
stability suggests that the complex may be stable in aque-
ous solution over long time frames. Later mass spectrometry 
experiments in aqueous solution likewise found a spectrum 
of complexes, among which again a dinuclear species was 
prominent [37].
2.2  Ferric Citrate as API of Auryxia
The API of Auryxia has a defined molar ratio of ferric iron 
to citrate anions, predominantly in the molar ratio of 2:2, 
whereas ferric citrate from commercial sources may have 
variable molar ratios of ferric iron and citric acid [36]. 
The API in Auryxia is described in US patents 7,767,851; 
8,338,642; 8,609,896 and 8,901,349 [51–54]; chemical anal-
ysis shows that this material contains a positively charged 
Fe(III) complex, presumably [Fe(H2O)6]3+, and a negatively 
charged complex,  [Fe2Citrate2(H2O)2]2− [36]. The major 
component in the API corresponds to the dinuclear com-
plex 2 (Fig. 2).
Unlike simple iron salts, the FCCCs in Auryxia help 
maintain ferric iron in solution at the varying conditions in 
different portions of the GI tract (i.e. at various pH levels) 
[36]. The relatively high solubility of the pharmaceutical-
grade ferric citrate in Auryxia contrasts with some commer-
cial iron salts, particularly at high pH; for example ferrous 
 (Fe2+) sulfate, an iron supplement commonly used to treat 
iron deficiency anemia, is practically insoluble at high pH 
[36, 43, 44]. An additional distinguishing characteristic of 
the FCCCs in Auryxia is their large surface area, which is at 
least 16 times that of commercial-grade ferric citrate [51]. 
High surface area generally favors rapid disintegration and 
therefore dissolution [55]. In the case of Auryxia, the rate 
of dissolution of its API at pH 8 is 3.08 times the rate of 
commercial-grade ferric citrate; the solubility of the Auryxia 
FCCCs is vital to the absorption of their iron [36, 51].
3  Absorption of Iron from Auryxia
Once the ferric citrate in Auryxia is ingested, the exact 
chemistry and structure of the resulting mixed citrate and 
ferric phosphate compounds in the stomach and intestines 
is unknown. It has long been thought that the low pH of 
the stomach is important for delivering soluble iron into 
the intestinal tract [43], although the solubility of Auryxia 
over a broad range of pH might make that factor less criti-
cal. Auryxia is believed to use the conventionally described 
and highly regulated enterocytic pathway of iron absorption 
[56], in which ferric iron (such as in the API of Auryxia) 
is enzymatically reduced to the ferrous state, absorbed pri-
marily in the duodenum, and finally transported into plasma 
and made available for erythropoiesis (Fig. 3) [57–59]. In 
contrast, when ferrous sulfate is used for iron supplementa-
tion, the reductive step in iron absorption may be bypassed, 
potentially leading to more rapid absorption, transferrin 
saturation and the release of substantial amounts of iron not 
bound to transferrin [60, 61]. Preliminary data from ongoing 
work suggest that the “conventionally” described pathway 
is the main route for iron absorption, but some contribu-
tions from other pathways (e.g. paracellular pathway [62], 
Fig. 2  Chemical structures of ferric citrate coordination complex ani-
ons determined by X-ray crystallography. Green-blue spheres repre-
sent iron atoms, red spheres represent oxygen atoms, and gray spheres 
represent carbon atoms. Cit citrate. Based on data from Matzapeta-
kis et al. [45]; Shweky et al. [46]; Bino et al. [47]; and Tenne et al. 
[45–48]
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transcellular pathway [63], gut microbiota [64]) have not 
been excluded (T. Ganz, private oral communication, March 
4, 2019 [manuscript in preparation]). Of further interest is 
that ferric iron, such as in Auryxia and unlike ferrous iron, 
is not easily oxidized [65]. Ferrous iron, during oxidation, 
can catalyze the formation of free radicals, causing GI 
mucosal cell damage and erosions of the GI mucosa that 
likely account for the reported increased incidence of GI 
adverse effects with ferrous iron compared with ferric iron 
products (Fig. 4) [65–71].
4  Phosphate Binding Capacity of Auryxia
Although some details of the iron chemical species pre-
sent in the GI tract after ingestion of Auryxia are unclear, 
the subsequent impact of the FCCCs on phosphate lev-
els is well established. The ferric iron from the API of 
Auryxia binds dietary phosphorus in the GI tract to form 
insoluble ferric phosphate, which precipitates and is 
excreted, thus decreasing intestinal phosphorus absorp-
tion and lowering blood phosphate levels [31, 72]. Mul-
tiple clinical studies have demonstrated the efficacy of 
Auryxia in lowering serum phosphate levels across the 
spectrum of CKD [72–76]. For example, results from 
a Phase 3, randomized, controlled trial in patients with 
CKD treated with dialysis showed that Auryxia effec-
tively reduced serum phosphate compared with placebo 
(analysis of covariance adjusted least squares mean treat-
ment difference: − 2.18 mg/dL [95% CI: − 2.59, − 1.77]; 
p < 0.0001; Fig. 5) [72]. These findings were confirmed 
in a recent retrospective chart review that showed that 
Auryxia reduced and maintained serum phosphate levels 
Fig. 3  Overview of iron absorption pathway. DcytB duodenal 
cytochrome B, DMT1 divalent metal transporter 1
Fig. 4  Iron misregulation and 
generation of reactive oxygen 
species
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over a 6-month period in adult dialysis patients with CKD 
[73]. Although the main focus of the studies was on con-
trol of hyperphosphatemia, improvements in iron param-
eters, such as increases in ferritin levels and transferrin 
saturation (TSAT), also were noted [72–74, 77]. Another 
consequence of the precipitation reaction between ferric 
iron (in Auryxia) and dietary phosphate is the release of 
citrate, which can be absorbed and converted to bicarbo-
nate, in theory helping to correct metabolic acidosis, a 
common complication of CKD [78, 79].
A non-calcium, iron-based phosphate binder, sucro-
ferric oxyhydroxide  (Velphoro®; Fresenius Medical Care 
North America, Waltham, MA, USA), was shown to 
effectively lower and maintain serum phosphate levels 
for over 1 year in patients receiving dialysis [80]. Treat-
ment with sucroferric oxyhydroxide did not significantly 
affect iron-related parameters such as TSAT, serum iron, 
and blood hemoglobin concentrations, which remained 
unchanged over the long-term [80].
5  Iron Supplementation with Auryxia
The efficacy of Auryxia for the treatment of iron deficiency 
anemia in patients with non-dialysis-dependent CKD (NDD-
CKD) was tested in a Phase 3 placebo-controlled trial [56]. 
In that study, treatment with Auryxia significantly improved 
hemoglobin levels, TSAT, and serum ferritin levels versus 
placebo (p < 0.001; Fig. 6). Diarrhea was the most common 
adverse reaction leading to discontinuation of Auryxia (2.6% 
of patients) in the 16-week, placebo-controlled trial; 12 
patients (10%) in the Auryxia treatment group discontinued 
Auryxia because of an adverse reaction, compared with 10 
patients (9%) in the placebo control arm [31]. Tolerability 
in the GI tract with Auryxia is consistent with the expected 
low level of reactive oxygen species, anticipated based on 
chemical considerations and regulated absorption, relative to 
ferrous iron products. Furthermore, the chelate effect (such 
as provided by the coordination of ferric iron by citrate) 
Fig. 5  Serum phosphate levels 
in patients with chronic kidney 
disease treated with dialysis. 
The displayed 4-week, open-
label, placebo-controlled period 
followed a 52-week, open-label, 
active-controlled period. Based 
on data from the study reported 
in Lewis et al. [72]
Fig. 6  Iron parameters in patients with iron deficiency anemia and 
non–dialysis-dependent chronic kidney disease. *Between-group dif-
ference of 0.84 g/dL (95% CI 0.58, 1.10; p < 0.001); †between-group 
difference of 18.4% (95% CI 14.6, 22.2; p < 0.001); ‡between-group 
difference of 170.3 ng/mL (95% CI 144.9, 195.7; p < 0.001). Adapted 
from Fishbane et al. [56]
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has been observed to improve GI tolerability in a study of 
a different oral iron product [81]. Notably, although citrate 
(a component of Auryxia) is known to promote absorption 
of aluminum in the GI tract, no changes in mean serum alu-
minum levels were seen after treatment with Auryxia [56, 
82, 83].
6  Iron Overload
As mentioned previously, long-term administration of 
medicinal iron raises a concern about eventual iron over-
load, and the risk is higher with IV iron products than with 
oral products, because IV administration bypasses the physi-
ologic regulation of iron absorption [25–28]. Indeed, with 
the exception of one patient who also received IV iron, 
iron overload has not been observed in patients after treat-
ment with Auryxia in clinical studies [31]. Furthermore, 
in patients with CKD treated with dialysis, treatment with 
Auryxia led to few serious adverse events in organ systems 
usually affected by iron overload [72]. Ferric iron, such as 
in Auryxia, is delivered relatively slowly and consistently, 
likely allowing the iron-regulatory peptide hormone, hep-
cidin, to slowly upregulate, as reflected in maintenance of 
clinically appropriate levels of iron markers [44, 84].
The iron-storage protein, ferritin, and the iron-carrier pro-
tein, transferrin, are both critical for iron homeostasis and 
have traditionally served as markers of iron status; however, 
there are caveats for their use as indicators of iron over-
load [57, 85–88]. Neither serum ferritin nor TSAT alone is 
accurate as a standalone measure of iron overload; serum 
ferritin is severely affected by inflammation, and TSAT, 
which is proportional to serum iron, is affected by the tim-
ing of the sample relative to IV or oral iron administration 
[86–88]. However, waiting at least 48 hours to draw blood 
after iron administration [89] allows a more accurate picture 
of iron overload using TSAT; TSAT tends to stabilize within 
2 weeks after beginning IV iron administration, so that high 
TSAT values at this point or later suggest iron overload or 
the inability to regulate iron; this timeline has not been stud-
ied extensively with oral iron [90–92]. In patients with iron 
deficiency anemia and NDD-CKD who were treated with 
Auryxia, 17.9% had transient elevations of TSAT ≥ 70%, yet 
none had iron overload [56]. Persistent increases in serum 
ferritin in the absence of clinically identifiable episodes of 
inflammation, but accompanied by increased TSAT, together 
may suggest iron overload. The only definitive outcome that 
indicates clinically significant iron overload is dysfunction 
of the end organs.
Auryxia and Riona share the same API, although the dos-
age forms and strengths differ (210 mg ferric iron per pill of 
Auryxia; approximately 62 mg ferric iron per pill of Riona) 
[31, 93]. The United States Food and Drug Administration 
(FDA) label for Auryxia carries a warning for iron overload 
recommending that iron parameters (e.g. serum ferritin and 
TSAT) should be assessed prior to initiating Auryxia and 
should be monitored while on therapy [31]. In a 56-week, 
Phase 3, randomized, controlled trial in patients with CKD 
treated with dialysis in which concomitant use of IV iron 
was permitted, 19% of patients treated with Auryxia had 
at least one measurement of serum ferritin > 1500 ng/mL, 
as compared with 10% of patients treated with the active 
controls (sevelamer carbonate and/or calcium acetate) [72]. 
Therefore, the FDA label includes a recommendation that 
patients receiving IV iron may require a reduction in dose or 
discontinuation of the IV iron therapy [31]. Because eleva-
tions in serum ferritin have been observed in previous stud-
ies of Auryxia and Riona [72, 94], a recent retrospective 
analysis of a Japanese Phase 3 trial in hemodialysis patients 
with hyperphosphatemia investigated the factors that may 
be associated with these elevations; the factor most strongly 
associated with elevations in serum ferritin, second only to 
the dose of Riona, was reduction in the dose of erythropoie-
sis-stimulating agent (ESA), presumably causing decreased 
utilization of iron for erythropoiesis [82, 84]. Importantly, 
no studies of Auryxia and Riona supported an association 
with clinically significant iron overload despite the observed 
elevations in serum ferritin levels [72, 82, 84, 94, 95].
7  Clinical Characteristics of Auryxia
7.1  Effects on Iron Levels When Used to Treat 
Hyperphosphatemia
The chemical attributes of Auryxia and its biological inter-
actions are reflected in its clinical characteristics. For exam-
ple, when used to treat hyperphosphatemia, it may also have 
beneficial effects on measures of iron status in disease set-
tings where functional or true iron deficiency and hyper-
phosphatemia coexist. In patients with CKD treated with 
dialysis, studies have shown that treatment with Auryxia 
reduces serum phosphate and improves iron parameters 
[72, 95]. In a Phase 3, 56-week, placebo- and active-
controlled trial in patients with dialysis-dependent CKD, 
Auryxia (dosed and titrated to maintain serum phosphate 
control) significantly improved iron parameters compared 
with active controls (sevelamer carbonate and/or calcium 
acetate) as early as Week 12 (ferritin: mean difference of 
281.8 ± 42.9 ng/mL at week 52, p < 0.001; TSAT: mean 
difference of 9.55% ± 1.58%, p < 0.001) [96]. Addition-
ally, two studies have suggested that Auryxia may reduce 
the need for IV iron when used as a phosphate binder in 
patients with CKD treated with dialysis [72, 96, 97]. Lower 
percentages of patients required IV iron in the Auryxia 
group compared with an active control group at all time 
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points over the 52-week active control period; at the end of 
this period, 85.4% and 69.0% of patients did not receive IV 
iron at week 52 in the Auryxia and active control groups, 
respectively (p < 0.001) [96]. The cumulative dose of IV iron 
was less in the Auryxia group as compared with the active 
control group over the entire 52-week active control period 
(median [interquartile range] dose of 12.9 [1.0–28.9] mg/
week with Auryxia vs 26.8 [13.4–47.6] mg/wk with active 
control; p < 0.001). Similarly, in the same study and over 
the same period, the cumulative dose of ESAs was lower in 
the Auryxia group compared with the active control group 
(median [interquartile range] dose of 5303 [2023–9695] 
units/week with Auryxia vs 6954 [2664–12,375] units/week 
with active control; p = 0.04) [96].
The effects of treatment with Auryxia could lead to clin-
ical outcomes that are different from those with other thera-
pies. Of note, treatment to a higher hemoglobin target has 
been associated with increased risk of vascular thrombosis, 
and higher ESA doses have been explored as a plausible 
mechanism for this increased risk [98]; therefore, a reduc-
tion of ESA dose may lower risk of cardiovascular events, 
thereby decreasing hospitalization. Infections are also an 
important driver of readmission after hospitalization in 
patients with CKD who are receiving hemodialysis [99]. 
In the aforementioned 56-week, Phase 3 trial in patients 
with end-stage renal disease on dialysis, treatment with 
Auryxia was associated with reductions in overall hospi-
talizations, cardiac-related hospitalizations, and infection-
related hospitalizations as compared with active control 
[100]. Treatment with Auryxia also reduced health-care 
costs; the cost savings were attributed to a decrease in use 
of IV iron and ESA and to a reduction in the number of 
hemodialysis sessions that were missed as a result of hos-
pitalizations [101, 102].
Thus, the ability of Auryxia to deliver iron, because of its 
chemical composition, is an added benefit when it is already 
being used to control phosphate levels and may improve 
clinical outcomes that are unrelated to hyperphosphatemia. 
The benefit of Auryxia as a therapy for the treatment of iron 
deficiency may be particularly important in light of recent 
research that has implicated IV iron therapy in non-alcoholic 
fatty liver disease (NAFLD) [103, 104]. In a longitudinal 
study of 7 patients undergoing IV iron therapy, hepatic pro-
ton density fat fraction and liver iron concentration levels 
increased significantly, suggesting that iron overload in these 
dialysis patients may have led to or exacerbated NAFLD 
[103].
7.2  Effects on Serum Phosphate Levels When Used 
to Treat Iron Deficiency Anemia
Additional studies have shown that treatment with 
Auryxia improves iron parameters in patients with CKD 
and iron deficiency anemia without negatively perturb-
ing serum phosphate when kidney function is sufficient 
to maintain normal phosphate levels [56, 105]. A post 
hoc analysis of the Phase 3 trial in patients with iron 
deficiency anemia and NDD-CKD showed that, when 
given as an iron replacement product, Auryxia did not 
significantly reduce serum phosphate compared with 
placebo among patients with baseline serum phosphate 
concentrations within the population reference range of 
2.5–4.5 mg/dL (Fig. 7) [105]. The effect of Auryxia on 
serum phosphorus depends on baseline phosphate lev-
els, declining only when the initial levels are excessive; 
the greatest reductions in serum phosphate were seen in 
patients with the highest baseline serum phosphate con-
centrations [105]. Therefore, as a converse of the situa-
tion in which Auryxia is used primarily as a phosphate 
binder, treating patients with iron deficiency anemia 
using Auryxia may have the additional benefit of reduc-
ing high serum phosphate and FGF23 levels. The evident 
lack of hypophosphatemia is interesting; one possibility 
is that patients with residual renal function may avoid 
hypophosphatemia during Auryxia treatment by retain-
ing more phosphate in the kidneys to compensate for 
losses by excretion in the gut. In fact, in a Phase 2 study, 
when patients with CKD stages 3–5 were given Auryxia 
as a phosphate binder, both mean serum phosphate and 
24-hour urinary phosphate significantly decreased com-
pared with control [75].
7.3  Effects on FGF23 Levels
The dual function of Auryxia in reducing serum phos-
phate and treating iron deficiency simultaneously 
decreases circulating levels of FGF23, a key phos-
phate-regulating hormone whose plasma concentration 
increases as CKD progresses [12, 56, 105]. In a Phase 
3 study in patients with NDD-CKD and iron deficiency 
anemia, levels of FGF23 were reduced significantly more 
between baseline and Week 16 with Auryxia treatment 
compared with placebo (Fig. 8) [56]. This was true both 
for the intact bioactive form of FGF23 (iFGF23) and for 
its carboxy-terminal cleavage product (cFGF23), whose 
biological activities are under investigation [106]. Simi-
larly, an open-label Japanese study in patients on hemo-
dialysis showed that treatment with Riona compared with 
lanthanum carbonate led to significantly lower levels of 
iFGF23, independent of phosphate levels (change from 
baseline in iFGF23: − 6160 vs − 1118 pg/mL, respec-
tively; p = 0.026) [97]. Although this conjecture is still 
speculative, reduction of FGF23 levels could have a ben-
eficial effect on the progression of CKD and cardiovascu-
lar disease. In mice treated with Auryxia, the concentra-
tions of FGF23 decreased and CKD disease progression 
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was slowed [107]. More definitive clinical trials will be 
needed to validate the hypothesis that ferric citrate slows 
CKD progression by lowering FGF23 [108].
8  Summary
Consistent with its chemistry and mechanism of action, 
Auryxia is effective both in reducing serum phosphate lev-
els in patients treated with dialysis and in improving iron 
parameters in CKD patients not on dialysis. Overall, across 
both CKD patient populations, treatment with Auryxia 
was considered to have good safety and was similarly well 
tolerated compared with other study treatments. In dialy-
sis patients, 21% discontinued Auryxia due to an adverse 
reaction versus 14% who discontinued active control (which 
patients had tolerated before enrollment); in patients with 
NDD-CKD, 10% discontinued Auryxia due to an adverse 
reaction versus 9% who discontinued placebo [31]. The 
balance of these characteristics distinguishes Auryxia from 
commercial-grade ferric citrate and differentiates it from 
other common therapies used to treat hyperphosphatemia 
and iron deficiency anemia in patients with CKD.
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